title: A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritis.
authors.forename: P V
authors.initials: PV
authors.lastname: Gardiner
authors.forename: A L
authors.initials: AL
authors.lastname: Bell
authors.forename: A J
authors.initials: AJ
authors.lastname: Taggart
authors.forename: G
authors.initials: G
authors.lastname: Wright
authors.forename: F
authors.initials: F
authors.lastname: Kee
authors.forename: A
authors.initials: A
authors.lastname: Smyth
authors.forename: R
authors.initials: R
authors.lastname: McKane
authors.forename: J
authors.initials: J
authors.lastname: Lee
authors.forename: M E
authors.initials: ME
authors.lastname: Rooney
authors.forename: E
authors.initials: E
authors.lastname: Whitehead
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab